This website uses cookies to ensure you get the best experience.

SmartCella and our selected partners use cookies and similar technologies (together “cookies”) that are necessary to present this website, and to ensure you get the best experience of it. If you consent to it, we will also use cookies for analytics purposes.

See our Cookie Policy to read more about the cookies we set.

You can withdraw and manage your consent at any time, by clicking “Manage cookies” at the bottom of each website page.

Select which cookies you accept

On this site, we always set cookies that are strictly necessary, meaning they are necessary for the site to function properly.

If you consent to it, we will also set other types of cookies. You can provide or withdraw your consent to the different types of cookies using the toggles below. You can change or withdraw your consent at any time, by clicking the link “Manage Cookies”, which is always available at the bottom of the site.

To learn more about what the different types of cookies do, how your data is used when they are set etc, see our Cookie Policy.

These cookies are necessary to make the site work properly, and are always set when you visit the site.

Vendors Teamtailor

These cookies collect information to help us understand how the site is being used.

Vendors Teamtailor
SmartCella

Request removal

To request deletion of your personal data, enter your email below and click the link in the email sent to you.

About SmartCella

SmartCella is a world-leading biotechnology company pioneering the future of targeted therapies by combining first-in-class delivery platforms with cutting-edge cell and gene therapies. The company has three units: SmartWise with the FDA-approved Extroducer, an endovascular device that enables direct tissue or organ infusion to hard-to-reach organs and tumors. SmartCella Solutions creating novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs. Procella with advanced capabilities within stem cell therapy development and cGMP manufacturing inhouse. Procella collaborates with AstraZeneca on a globally licensed cardiac stem cell therapy to repair parts of the heart damaged from a heart attack and has a growing pipeline of stem cell therapies.

SmartCella, founded in 2014, is based in Tullinge, Sweden and has approximately 80 employees, mainly scientists and researchers, with around 20 different nationalities represented.

Co-workers 82